Acumen Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Acumen Pharmaceuticals has a total shareholder equity of $267.0M and total debt of $29.9M, which brings its debt-to-equity ratio to 11.2%. Its total assets and total liabilities are $310.1M and $43.2M respectively.
Key information
11.2%
Debt to equity ratio
US$29.90m
Debt
| Interest coverage ratio | n/a |
| Cash | US$243.52m |
| Equity | US$266.97m |
| Total liabilities | US$43.15m |
| Total assets | US$310.13m |
Recent financial health updates
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Jan 07Recent updates
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
Sep 28Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
Jun 30We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Jan 07Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 01Financial Position Analysis
Short Term Liabilities: ABOS's short term assets ($246.6M) exceed its short term liabilities ($13.0M).
Long Term Liabilities: ABOS's short term assets ($246.6M) exceed its long term liabilities ($30.2M).
Debt to Equity History and Analysis
Debt Level: ABOS has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ABOS's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABOS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ABOS has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 47.2% each year.